Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

A legfontosabb adatok

Ki végzi
VA Office of Research and Development
Hol
The Bronx és West Orange (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
36 fő vett részt
Kezdés
2021. márc. 1.
Befejezés
2026. aug. 24.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Romosozumab
  • Denosumab
  • Placebo
A regiszteradat frissítve
2026. szeptember 21.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Motor-complete or incomplete spinal cord injury (SCI) [all levels of lesion] classified using International Standards for Neurological Classification for Spinal Cord Injury (ISNCSCI) impairment scale] as ISNCSCI score A-C
  • Duration of injury >3 years
  • Males (18-65 years old) and females (premenopausal, between the ages of 18 and 55 years old)
  • Areal bone mineral density (aBMD) at the distal femur <1.0 g/cm2 (determined at screening)

Ki nem vehet részt

  • History of prior bone disease (Paget's hyperparathyroidism, etc.)
  • Men with known hypogonadism prior to spinal cord injury (SCI)
  • Anabolic therapy longer than six months duration after spinal cord injury (SCI)
  • Glucocorticoid administration longer than three months duration within the last year, and/or prescribed moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute spinal cord injury (SCI)
  • Heterotopic ossification (HO) of the knee region (the distal femoral epiphysis is the primary endpoint); HO to any other boney region will not prevent study participation as long as contraindicated medications have not been prescribed)
  • Active and/or history of coronary heart disease or stroke within the past year
  • Endocrinopathies (hyperthyroidism, Cushing's disease or syndrome, etc.)
  • Severe underlying chronic disease (e.g., COPD, end-stage heart disease, chronic renal failure)
  • Current diagnosis of cancer or history of cancer
  • Prescribed a bisphosphonate for HO, or prescribed any other agent to treat osteoporosis other than calcium and vitamin D
  • Long-bone fracture of the leg within the past year
  • Postmenopausal women
  • Chronic alcohol abuse
  • Hypocalcemia
  • Pregnancy
  • Electrical stimulation of the lower extremities
  • Osteosarcoma
  • Life expectancy less than 5 years

Helyszínek itt: Egyesült Államok

  • James J. Peters VA Medical Center, Bronx, NYThe Bronx, Egyesült Államok
  • Kessler Institute for RehabilitationWest Orange, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD).

A teljes eredeti leírásKevesebb

The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur <1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab.

A vizsgálat 3 csoportja

  • Romosozumab Treatment (baseline to month 11)A vizsgált kezelés

    Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.

    Kezelés: Romosozumab

  • Placebo (baseline to month 12)Placebo, összehasonlításként

    Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.

    Kezelés: Placebo

  • Denosumab (month 12 to month 24)Már használt kezelés, összehasonlításként

    Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).

    Kezelés: Denosumab

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. szeptember 21.